Introduction
It has been shown that interaction of the chemokine SDF-1 with the CXCR4 receptor is an important component of the mechanism of retention of stem cells in the bone marrow.
1,2 SDF-1 also upregulates the expression of adhesion molecules, such as VLA-4, which mediate the adhesion of stem cells to bone marrow stroma. 3, 4 The mechanism of stem cell mobilization using the growth factor G-CSF involves stimulation of CD34 þ stem cell production within the bone marrow and proteolytic cleavage of VCAM-1, the ligand for VLA-4. 5 It has been proposed that CXCR4/SDF-1 interaction is also necessary for G-CSF-mediated mobilization of stem cells.
6 AMD3100 mobilizes CD34 þ cells 7, 8 via a proposed mechanism of inhibition of the SDF-1/CXCR4 interaction responsible for stem cell homing and retention. Furthermore, the synergistic effect of AMD3100 and G-CSF observed in CD34 þ progenitor cell mobilization is consistent with their respective mechanisms of action. A recent review including the mechanisms of stem cell mobilization has been published by Cashen et al. 9 AMD3100 has been effective in mobilizing CD34 þ cells for autologous transplant in a number of diseases, including non-Hodgkin's lymphoma (NHL), 10 multiple myeloma (MM) 10 and Hodgkin's disease (HD). 11 Clinical studies show that AML cells may be mobilized by AMD3100 via CXCR4 inhibition, and preclinical studies suggest the same for CLL cells. [12] [13] [14] Recent clinical experience also shows that plasma cell leukemia (PCL) cells can be mobilized by AMD3100 (AnorMED, unpublished data, 2006). Due to these concerns, AML, CLL and PCL patients are excluded from AMD3100 trials. AMD3100 trials have generally excluded patients who could not mobilize or collect sufficient cells for transplant (poor mobilizers), with the exception of two early phase 2 AMD3100 trials: AMD3100-2101 10 and AMD3100-2102. 15 In the study AMD3100-2101, 9/25 patients failed mobilization with G-CSF alone but proceeded to collect a transplantable dose of CD34 þ cells when remobilized with AMD3100 plus G-CSF. Obtaining cells for transplant from poor mobilizers is a significant medical need and the results from trials AMD3100-2101 and 2102 led to the conclusion that the drug should be made available to these patients via a Single Patient Use (SPU) protocol. The SPU protocol was subsequently expanded for multiple patient use and termed the Compassionate Use Protocol (CUP). Both the SPU protocol and CUP were approved by the US Food and Drug Administration (FDA) for patients who had previously failed other mobilization regimens. CUP was initiated first in the United States and then in Australia and Canada allowing requests for AMD3100 treatment to be addressed in an urgent manner, such as when a patient required remobilization within 1-2 weeks. Access to AMD3100 treatment through CUP was available to patients at sites regardless of involvement in AMD3100 research trials. SPU protocols allow patients who do not qualify for ongoing trials to have access to unlicensed drugs. 16 The AMD3100 SPU protocol and CUP conform to regulatory standards, but the data may be limited both in amount sent by the site and the quality. However, these data may be valuable to assess the outcomes of patients treated with less common laboratory abnormalities or unusual disease states not evaluated otherwise. While the design of CUP does not include a comparative group as a control, the patients enrolled had previously received a conventional mobilization regimen, which resulted in mobilization of insufficient CD34 þ cells for transplant.
This report evaluates the outcome of proven poor mobilizers whose prior history and outcomes were verified by auditing of data at the enrolling sites in the United States. Approximately 70% of these patients were successfully mobilized resulting in a total of X2 Â 10 6 CD34 þ cells per kg being collected by apheresis. The safety profile of AMD3100 was similar to that seen in previous studies. Following transplant, patients engrafted durably.
Materials and methods

Enrollment into CUP
Physicians were required to complete regulatory documents including informed consent and agree to follow the FDAapproved protocol. Entry into the protocol was limited to patients who had previously failed to proceed to apheresis due to low peripheral blood (PB) CD34 þ cell counts (usually 10 cells per ml or less) or based on apheresis yield were unlikely to collect the minimum number for a single transplant, usually 2 Â 10 6 CD34 þ cells per kg. In almost all cases this assessment was made from the first apheresis following the mobilization.
Protocol inclusions/exclusions
Patients were required to meet the criteria listed below for treatment in CUP. Protocol design, administration of G-CSF and AMD3100
The sequence of events for treatment in CUP is shown in Figure 1 . Patients underwent history, physical examination, chest X-ray, electrocardiogram and laboratory evaluations. They were given G-CSF as per site preference, typically as a subcutaneous dose of 10 mg/kg each morning for 4 days. At approximately 2200 on the fourth day of treatment they were given a subcutaneous dose of 240 mg/kg AMD3100. On the morning of the fifth day G-CSF was administered and apheresis (blood volumes as per site preference) began at approximately 10 h after the AMD3100 dose. Administration of G-CSF, apheresis and administration of AMD3100 were repeated daily until the patient collected sufficient cells for transplantation (minimum 2 Â 10 PMN and PLT recovery were measured as per site practices and patients were monitored for graft durability up to 1 year post-transplant. All laboratory evaluations were performed at local site laboratories.
Outcome criteria
Successful mobilization was defined as collection of a total of X2 Â 10 6 CD34 þ cells per kg during mobilization with AMD3100 plus G-CSF. Prospective criteria for PMN and PLT engraftment were not given. The majority of sites defined PMN engraftment as the first of 3 consecutive days with a PMN count X0.5 Â 10 9 per liter or the first day X1.0 Â 10 9 per liter. PLT engraftment was typically defined as the first day where the PLT count was X20 Â 10 9 per liter without PLT transfusion.
Adverse event reporting
Any adverse events (AEs) were reported to the sponsor if they occurred from the time of the first dose of AMD3100 until 30 days after the last apheresis or until the first dose of myeloablative chemotherapy (whichever occurred first). Serious adverse events (SAEs) were reported to the sponsor if they occurred from the time of the first dose of AMD3100 until 6 months post-transplant. All AEs and SAEs were graded by the investigator in terms of severity and potential relationship to AMD3100. Graft failure up to 12 months post-transplant was reported as an SAE.
Data audit, definition of study population Records submitted to the sponsor for MM, NHL and HD patients enrolled in CUP were audited against source documents at sites meeting the following criteria: most patients enrolled in CUP, more than three patients enrolled in each disease group and/or sites conducting a company-sponsored AMD3100 study. Data audits included all patients at a site, regardless of success or failure of outcome. The primary focus of the audit was to confirm safety, documentation of the prior mobilization failure, the outcome of AMD3100 mobilization, the outcome of transplantation and graft durability. Data audit visits were performed between 23 January 2006 and 16 May 2006.
Results
At the time of the data audit more than 200 patients were enrolled in CUP, including both adult and pediatric with AML and solid tumors. This report comprises audited outcomes and safety data for a subgroup of 115 patients with NHL, MM or HD at 22 sites who met the criteria for data audit as described. These 115 patients represent over 80% of the total NHL, MM and HD patients enrolled in CUP at the time of the data audit. A total of 17 sites contributed p6 patients each, the remaining 5 sites contributed 7, 9, 10, 14 and 15 patients each. The original CUP contained a statement allowing physicians judgment as to a patient's inability to mobilize cells for transplant. The protocol was later amended to require documented failure of a prior mobilization. Two patients (one NHL and one HD, both previously given cytokines only for mobilization) who had not failed prior mobilization according to the CUP criteria were identified in the audit. Both patients required five or more aphereses to collect the minimum number of cells and are included in this report as they were considered to be poor mobilizers. One additional NHL patient included in this report failed prior chemotherapy mobilization and did not proceed to apheresis following mobilization on CUP. This patient was considered a mobilization failure.
Patient characteristics are shown in Table 1 , including laboratory values at screening and the weight used for calculation of AMD3100 dose. The majority of patients were Caucasian and male. Regimens used for prior mobilization were separated into two groups: chemotherapy with or without cytokines and cytokines only. The distribution of chemotherapy mobilization versus cytokine mobilization was NHL-29/34, MM-24/11 and HD-8/9. Where pre-mobilization PB CD34 þ cell counts were available, 475% were o10 cells per ml; and the remainder were in the range 10.1-16.3 cells per ml. In all disease groups, patients had received a median number of 2 prior to chemotherapy regimens. The median value and range of CBC results for patients at entry to CUP are shown in Table 1 , PLT count was o100 Â 10 9 per liter for 19% of all patients.
Waivers for specific entry requirements were granted to very ill patients who it was felt would benefit from enrollment in CUP. A number of patients had a PLT count less than 50 Â 10 9 per liter, ANC as low as 0.4 Â 10 9 per liter, and liver function tests up to 2.5 times beyond the upper limit of normal (data not shown). In addition, several patients had creatinine clearance as low as 30 cc/min (data not shown). The G-CSF dose administered was 10 mg/kg for the majority of patients with a range of 5-16 mg/kg and a median dose of 10.2 mg/kg. G-CSF was administered in the morning between 0400 and 1100 for the majority of patients. A small number of patients (o10) received at least one dose of G-CSF as late as 2200. The dose of 240 mg/kg AMD3100 was typically administered between 2100 and 2300. Ten patients received at least one dose of AMD3100 as late as 0000 (midnight) and one received doses as early as 2000. Apheresis typically began between 0700 and 1000 the following morning.
The safety profile showed that of the AMD3100-related AEs, 2 (1.6%) were severe, 17 (13.6%) were moderate and 106 (84.8%) were mild. The most common AEs related to AMD3100 were gastrointestinal (diarrhea-17.4%, nausea-9.6%), injection site (erythema-15.7%) and nervous system (paresthesia and oral paresthesia-6.9%) ( Table 2) . Two severe AEs were AMD3100 related; these AMD3100 þ G-CSF can successfully mobilize G Calandra et al Patients are counted once only for each adverse event, although the patient may report the same event several times. Percentages are calculated using the number of patients (N) in that group as the denominator.
AMD3100 þ G-CSF can successfully mobilize G Calandra et al were headache experienced by one patient and nightmares experienced by one other. Nine patients experienced nonserious AMD3100-related decreases in PLT count. These decreases occurred immediately following apheresis, suggesting they may have been related to the apheresis procedure. No AMD3100-related SAEs were experienced by the group of 115 data-audited patients. There were 15 deaths among the 115 patients, none were related to AMD3100. Two deaths occurred within 30 days of the last dose of AMD3100. These deaths were attributed to disease progression and multiple organ failure due to chemotherapy. One AMD3100-related SAE of worsening abdominal pain was experienced by a patient entered in CUP during the time period studied, although this patient was not among the 115 presented in this report.
Data including apheresis yield, transplantation rates and engraftment are shown in Table 3 . The median time between prior mobilization failure and treatment in CUP was approximately 1 month. The success of patients collecting X2 Â 10 6 CD34 þ cells per kg was 466% overall and was higher for patients previously failing chemotherapy mobilization than for cytokine mobilization in the NHL and MM groups, but not the HD group. The collection of follow-up data was subject to patient's consent to laboratory evaluations up to 12 months posttransplant. For all patients graft failure was reported as an AE up to 12 months post-transplant. Laboratory results to assess graft durability up to 12 months after transplant were available for 36 patients (23 NHL, 6 MM and 7 HD). Of the 36 patients, 34 (94.4%) patients met the following definition of graft durability: ANC 41.0 Â 10 9 per liter and PLTs 420 Â 10 9 per liter. Of the two patients who did not meet these criteria, one mobilized only 0.2 Â 10 6 CD34 þ cells per kg during CUP and was transplanted with cells pooled from various collections. The remaining patient experienced disease relapse resulting in death. An additional patient had a SAE of graft failure reported at the time of death though PMN, hemoglobin and PLT counts were found to be inconsistent with graft failure. No additional reports of graft failure were made. Discussion AMD3100 provides additional benefit to G-CSF mobilization in terms of the number of cells collected and the number of days to collect X2 Â 10 6 CD34 þ cells per kg, 10 both of which are beneficial to patients seeking to proceed to autologous stem cell transplantation. The benefit of AMD3100, compared to other mobilization strategies is not straightforward to quantify. A comparable study to AMD3100 CUP is difficult to identify in terms of patient's age, disease, prior treatment, apheresis procedures, criteria for success and other factors. For example, in a review by Boeve et al., 17 the success of a second mobilization following a failed mobilization was based upon the ability to provide sufficient cells for transplant by combining cells from both mobilizations. Using this definition, when high-dose G-CSF (32 mg/ kg per day) or a combination of G-CSF (10 mg/kg per day) plus GM-CSF (5 mg/kg per day) was used, the success rate was 73%. However, the median apheresis yield for the high dose G-CSF group was 2.2 Â 10 6 CD34 þ cells per kg and that for G-CSF plus GM-CSF was 1.6 Â 10 6 CD34 þ cells per kg. These yields suggest the success rate of collecting X2 Â 10 6 CD34 þ cells per kg by remobilization with G-CSF or G-CSF plus GM-CSF was approximately 50%. Lefrere et al. 18 reported in a letter to the editor a success rate of 65% for remobilization using G-CSF (10 mg/kg) 7 days after failure of mobilization with chemotherapy plus G-CSF (5 mg/kg). Whether the prior low dose of G-CSF or the short interval after prior mobilization influenced the rate of success is uncertain. Goterris et al. 19 recently reported a success rate of 51% using either G-CSF (10 mg/kg) or chemotherapy plus G-CSF (5 mg/kg) in 41 patients of which 19 had NHL, HD or MM. This contrasts to a study from the late 1990s 20 where G-CSF (10-32 mg/kg) was successful in 24% of 50 patients. It appears that the success rate for a second mobilization is 20-50% with the exception of the Lefrere report of 65%.
The overall success rates in this analysis of CUP data for NHL, MM and HD patients were better than in most prior reports at 60.3, 71.4 and 76.5%, respectively. The success rates for patients who previously failed chemotherapy mobilization were 65.5, 75.0 and 75.0% for NHL, MM and HD, respectively. These rates exceed the success rate of the Lefrere report for patients who initially failed chemotherapy mobilization.
Previous AMD3100 trials have shown the drug to be generally safe. 11, 21, 22 The most common AEs considered related to AMD3100 are diarrhea, injection site erythema and nausea/vomiting. The safety profile of AMD3100 in the CUP population was similar to that seen in patients in two phase 2 trials 10,23 despite potentially more severe background conditions. G-CSF was administered concomitantly with AMD3100 and may have contributed to some AEs including bone pain, general fatigue, headache, nausea/vomiting, and changes in blood chemistry including increased alkaline phosphatase. 9, 24 The cells collected following mobilization with AMD3100 plus G-CSF engrafted and the graft remained durable. Median times to engraftment of 11 days AMD3100 þ G-CSF can successfully mobilize G Calandra et al post-transplant for PMNs and 18 days post-transplant for PLTs were similar to those seen in a previous study by Flomenberg et al., 10 where the median times post-transplant to PMN and PLT engraftment were 10-11 days and 16 days, respectively. It should be noted that CUP patients had fewer PMN and PLT measurements taken to document the precise day of PLT engraftment than in other AMD3100 trials. This is one of the largest prospective trials of a new treatment for patients who mobilize poorly. However, there are some potential limitations of the data set. The standard of care of the patients was not monitored and sites were not trained in the conduct of CUP. However, the majority of sites were those conducting companysponsored trials and therefore had knowledge of the conduct of AMD3100 trials and had experience with the drug. This, hopefully, decreased the risk of treatment or data collection errors. A more significant limitation was the ability to retrieve case report form (CRF) pages from the sites. Data collection was significantly improved for dataaudited patients as sites were encouraged to provide CRFs to the sponsor prior to the audit visits. Long-term followup data were limited as some patients had left their CUP physician to return to their referring physician prior to data being submitted. Another limitation was that the audit reviewed only data reported on CRFs and with the exception of principal data did not search patient records. For the most part these limitations should not adversely affect the report, but do limit the ability to analyze some factors such as details of prior chemotherapy regimens or past disease.
The reason for the superior response with AMD3100 plus G-CSF in patients who had previously failed a chemotherapy mobilization is unclear. Assuming that progenitors are held within the bone marrow via the chemotactic effects of SDF-1 on CXCR4-expressing cells (including CD34 þ cells), chemotherapy depletion of progenitors and WBCs could significantly affect the homeostasis, whereby the bone marrow contains an excess of SDF-1. 25 This imbalance may inhibit the release of progenitors, particularly in patients who have depleted bone marrow (such as CUP patients) and is corrected by administration of AMD3100.
There have been no comparative randomized trials in poor mobilizers of AMD3100 plus G-CSF versus G-CSF alone or other regimens. The comparative partially randomized study reported by Flomenberg 10 where the patient served as his/her own control did show a significant benefit in poor mobilizers of AMD3100 plus G-CSF compared to G-CSF alone. A comparative study of AMD3100 plus G-CSF (10 mg/kg) versus G-CSF (10 mg/ kg) alone is being initiated in NHL and MM patients failing prior chemotherapy mobilization with G-CSF. This study should help to identify the better mobilization strategy. Stiff 26 has proposed that the best approach is to prevent poor mobilization by using optimal combination treatment up front. Until such an approach is widely adopted, the results from the CUP program show that AMD3100 in conjunction with G-CSF may be very beneficial for patients failing prior mobilization.
